Biomarker Testing for People With Advanced Lung Cancer in England

Jana B. Adizie, Judith Tweedie, Aamir Khakwani, Emily Peach, Richard Hubbard, Natasha Wood, John R. Gosney, Susan V. Harden, Paul Beckett, Sanjay Popat, Neal Navani

Research output: Journal PublicationArticlepeer-review

16 Citations (Scopus)


Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.

Original languageEnglish
Article number100176
JournalJTO Clinical and Research Reports
Issue number6
Publication statusPublished - Jun 2021
Externally publishedYes


  • Biomarkers
  • Mutation testing
  • Non–small cell lung cancer
  • Personalized medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Biomarker Testing for People With Advanced Lung Cancer in England'. Together they form a unique fingerprint.

Cite this